Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Jackman DM, et al. Among authors: janne pa. Clin Cancer Res. 2006 Jul 1;12(13):3908-14. doi: 10.1158/1078-0432.CCR-06-0462. Clin Cancer Res. 2006. PMID: 16818686
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA. Jackman DM, et al. Among authors: janne pa. J Clin Oncol. 2007 Mar 1;25(7):760-6. doi: 10.1200/JCO.2006.07.5754. Epub 2007 Jan 16. J Clin Oncol. 2007. PMID: 17228019 Clinical Trial.
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA. Koivunen JP, et al. Among authors: janne pa. Clin Cancer Res. 2008 Jul 1;14(13):4275-83. doi: 10.1158/1078-0432.CCR-08-0168. Clin Cancer Res. 2008. PMID: 18594010 Free PMC article.
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA. Sasaki T, et al. Among authors: janne pa. Cancer Res. 2011 Sep 15;71(18):6051-60. doi: 10.1158/0008-5472.CAN-11-1340. Epub 2011 Jul 26. Cancer Res. 2011. PMID: 21791641 Free PMC article.
New targetable oncogenes in non-small-cell lung cancer.
Oxnard GR, Binder A, Jänne PA. Oxnard GR, et al. Among authors: janne pa. J Clin Oncol. 2013 Mar 10;31(8):1097-104. doi: 10.1200/JCO.2012.42.9829. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401445 Free PMC article. Review.
492 results